Brian Woodard

Paralegal Specialist
Full contact info

I help innovators and icons protect their ideas and reputations in a changing world.

Passions

Spending time with friends and family, traveling, playing an occasional round of golf and rooting for the Seahawks.

Experience

WSO2 to Be Acquired by EQT

May 6, 2024

Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).

Read more

Related contacts

Nick Davis
Partner, Seattle
Sangitha Palaniappa
Associate, Palo Alto
Caitlin Breitenbruck
Associate, Seattle
Edward (Teddy) Nimetz
Associate, New York
Anne Luquette
Associate, San Francisco
Brian Woodard
Paralegal Specialist, Seattle
David Silverman
Partner, New York
Yuri Weigel
Special Counsel, Seattle
Stephanie Gentile
Partner, New York
Jonathan Rivinus
Partner, Colorado
Megan Browdie
Partner, Washington, DC
John Robertson
Partner in Charge – Seattle, Seattle
Amelia Runyan Davis
Partner, Colorado

Related Practices & Industries

World View to List in $350 Million SPAC Deal

January 20, 2023

Cooley advised World View, a leader in stratospheric exploration and flight, on its definitive business combination agreement with publicly traded special purpose acquisition company Leo Holdings Corp. II. The transaction will result in World View becoming a publicly listed company. Partners Alex Kassai, Milson Yu and Miguel Vega led the Cooley team advising World View.

Read more

Related contacts

Milson Yu
Partner, Palo Alto
Miguel J. Vega
Partner, Boston
Thomas Connors
Partner, Boston
Howard Morse
Partner, Washington, DC
Stephanie Gentile
Partner, New York
Barbara Mirza
Partner, Los Angeles Santa Monica
Christopher Kimball
Partner, Washington, DC
Kevin King
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Ryan Montgomery
Special Counsel, Boston
Yuri Weigel
Special Counsel, Seattle
Sharon Connaughton
Special Counsel, Washington, DC
Bridget R. Reineking
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Shannon MacMichael
Special Counsel, Washington, DC
Nicolas Francis
Associate, San Francisco
Elizabeth Galvin
Associate, Boston
Lucy Bauer
Associate, Seattle
Jarrett Burks
Associate, London
Phoebe Huang
Associate, Seattle
Erica Pedersen
Associate, Boston
Michelle Peleg
Associate, San Francisco
Tyler McClure
Associate, San Francisco
Jesse Schulman
Associate, Washington, DC
Brian Woodard
Paralegal Specialist, Seattle

Related Practices & Industries

Bonum Therapeutics Closes $93 Million Series A Financing

November 15, 2022

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.

Related contacts

Sonya Erickson
Partner and Business Department Chair, Seattle
Colleen Badgley
Partner, Seattle
Brian Woodard
Paralegal Specialist, Seattle
Arlo Sporn
Associate, Seattle

Related Practices & Industries

Helion Energy Raises $2.2 Billion With Series E Round

November 11, 2021

Cooley advised Helion Energy, a clean energy company committed to creating a new era of plentiful, zero-carbon electricity from fusion, on its $500 million Series E financing round, which also includes an opportunity for an additional $1.7 billion tied to Helion reaching key performance milestones. Lawyers Sonya Erickson, Colleen Badgley, Ashley Brown, Justine Chiu and Jasjit Grewal led the Cooley team advising Helion.

Read more

Related contacts

Sonya Erickson
Partner and Business Department Chair, Seattle
Colleen Badgley
Partner, Seattle
Richard G.S. Lee
Associate, Washington, DC
John Sellers
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Eileen Marshall
Partner, Washington, DC
Phoebe Huang
Associate, Seattle
Brian Woodard
Paralegal Specialist, Seattle

Related Practices & Industries

Eliem Therapeutics – $92 Million IPO

August 10, 2021

Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.

Related contacts

Alan Hambelton
Partner, Seattle
Sonya Erickson
Partner and Business Department Chair, Seattle
Stephen Rosen
Partner, London
Willy Cowles
Associate, Seattle
Brian Woodard
Paralegal Specialist, Seattle

Related Practices & Industries

View more